The Journey to Diagnosis in AS/Axial SpA: The Impact of Delay

Musculoskeletal Care

Volumn 12, Issue 4, 2014, Pages 221-231

  Martindale, J ^a,b   Goodacre, L ^c  

^a Wrightington Wigan and Leigh NHS Trust   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c Research and Development NHS   (United Kingdom)

Author keywords

Ankylosing spondylitis axial SpA; Consequences; Delayed diagnosis

Indexed keywords

ADULT; DELAYED DIAGNOSIS; EMOTION; EPIDEMIOLOGY; FEMALE; HUMAN; INTERVIEW; MALE; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGY; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING;

ADULT; DELAYED DIAGNOSIS; EMOTIONS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; STRESS, PSYCHOLOGICAL;

EID: 84914166568     PISSN: 14782189     EISSN: 15570681     Source Type: Journal    
DOI: 10.1002/msc.1080     Document Type: Article

References (49)

1. Anderson R, Bury M (1988). Living With Chronic Illness: The Experience of Patients and their Families. London: Unwin Hyman.
2. Brandt HC, Spiller I, Song IH, Vahldiek J, Rudwaleit J, Sieper J (2007). Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Annals of the Rheumatic Diseases 66: 1479-84.
3. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998). Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism 41: 58-67.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002). Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359: 1187-93.
5. Bury M (1982). Chronic illness as biographical disruption. Sociology of Health and Illness 4: 167-82.
6. Calin A, Garrett S, Whitelock H, Kennedy G, O'Hea J, Mallorie P, Jenkinson T (1994). A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index (BASFI). Journal of Rheumatology 21: 2281-5.
7. Charmaz K (1991). Good Days, Bad Days: The Self in Chronic Illness and Time. New Brunswick, NJ: Rutgers University Press.
8. Charmaz K (2006). 'Measuring pursuits, marking self: Meaning construction in chronic illness. International Journal of Qualitative Studies on Health and Well-being 1: 27-37.
9. Chilton-Mitchell L, Martindale J, Hart A, Goodacre L (2013). Normative values for the Bath Ankylosing Spondylitis Metrology Index in a UK population. Rheumatology 52: 2086-90.
10. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003). Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis and Rheumatism 48: 3230-6.
11. Dougados M, Dijkmans B, Khan M, Maksymowych W, Van der Linden S, Brandt J (2002). Conventional treatments for ankylosing spondylitis. Annals of the Rheumatic Diseases 61: iii40-50.
12. Englander M (2012). The interview: Data collection in descriptive phenomenological human scientific research. Journal of Phenomenological Psychology 43: 13-35.
13. Feldtkeller E, Bruckel J, Khan MA (2000). Scientific contributions of ankylosing spondylitis patient advocacy groups. Current Opinion in Rheumatology 12: 239-47.
14. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003). Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatology International 23: 61-6.
15. Frank A (1995). The Wounded Story Teller: Body, Illness and Ethics. Chicago, IL: University of Chicago Press.
16. Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A (1994). A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Journal of Rheumatology 21: 2286-91.
17. Gran JT, Skomsvoll JF (1997). The outcome of ankylosing spondylitis: A study of 100 patients. British Journal of Rheumatology 36: 766-71.
18. Haywood K, Garratt A, Jordan K, Jordan K, Healey E, Packman J (2010). Evaluation of the ankylosing spondylitis quality of life (EASi-QoL): Reliability and validity of a new patient reported outcome measure. Journal of Rheumatology 37: 2100-9.
19. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006). Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 54: 2136-46.
20. Holloway I, Sofaer-Bennett B, Walker J (2007). The stigmatisation of people with chronic back pain. Disability and Rehabilitation 29: 1456-64.
21. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM (1988). A scale for the estimation of sleep problems in clinical research. Journal of Clinical Epidemiology 41: 313-21.
22. Jenkinson TR, Mallorie PA, Whitelock H, Kennedy G, Garrett SL, Calin A (1994). Defining spinal mobility in ankylosing spondylitis: The Bath Ankylosing Spondylitis Metrology Index. Journal of Rheumatology 21: 1694-8.
23. Johnsen K, Gran JT, Dale K, Husby G (1992). The prevalence of ankylosing spondylitis among Norwegian Samis (Lapps). Journal of Rheumatology19: 1591-4.
24. Jois R, Macgregor A, Gaffney K (2008). Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatology 47: 1364-6.
25. Keat A (2010). Ankylosing spondylitis. Medicine 38: 185-9.
26. Khan MA (2002). Update on spondyloarthropathies. Annals of Internal Medicine 136: 896-907.
27. Khan MA (2009). Ankylosing Spondylitis. New York, NY: Oxford University Press.
28. Lincoln Y, Guba E (1985). Naturalistic Inquiry. London: Sage Publications Limited.
29. Lorig K, Brown BW Jr, Ung E, Chastain R, Shoor S, Holman HR (1989). Development and evaluation of a scale to measure the perception of self-efficacy of people with arthritis. Arthritis and Rheumatism 32: 37-44.
30. Mansour M, Gurtej S, Cheema SM, Naguwa M, Greenspan A, Borchers A, Keen C, Gershwin ME (2007). Ankylosing spondylitis: A contemporary perspective on diagnosis and treatment. Seminars in Arthritis and Rheumatism 36: 210-23.
31. Narin S, Richards HB, Satoh M, Sariento M, Davidson R, Shuster J, Sobel E, Hahn P, Reeves WH (2004). Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Archives of Internal Medicine 164: 2435-41.
32. National Ankylosing Spondylitis Society (2010). Looking Ahead. Best practice for the care of people with ankylosing spondylitis (AS). Available at http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCAQFjAA&url=http%3A%2F%2Fnass.co.uk%2Fdownload%2F4cceacf2c1d0a&ei=yummU_aHN4ma0AWc5oHoBw&usg=AFQjCNFAezHT1QhisvoOZNxHPWBA2Edliw [Accessed March 2014].
33. Ozgocmen S, Khan MA (2012). Current concept of spondyloarthritis: Special emphasis on early referral and diagnosis. Current Rheumatology Reports 14: 409-14.
34. Reid K, Flowers P, Larkin M (2005). Exploring lived experience. The Psychologist 18: 20-3.
35. Richie J, Lewis J, McNaughton Nicholls, C, Ormston R (2013). Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: Sage.
36. Ritchie J, Lewis J (2003). Qualitative Research Practice. London: Sage.
37. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J (2004a). How to diagnose axial spondyloarthritis early. Annals of the Rheumatic Diseases 63: 535-43.
38. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004b). Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Annals of the Rheumatic Diseases 63: 665-70.
39. Rudwaleit M, Niewerth M, Listing J, Zeidler H, Zink A (2005). Disease activity over one year in early ankylosing spondylitis in an observational cohort study (GESPIC). Annals of the Rheumatic Diseases 64: 65.
40. Sieper J, Rudwaleit M (2005). How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Annals of the Rheumatic Diseases 64: iv61-4.
41. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann K-G, Landewé R, Maksymowych W, van der Heijde D (2009). The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Annals of the Rheumatic Diseases 68: ii1-44.
42. Smith J (2004). Reflecting on the development of interpretative phenomenological analysis and its contribution to qualitative research in psychology. Qualitative Research in Psychology 1: 39-54.
43. Smith J, Flowers P, Larkin M (2012). Interpretative Phenomenological Analysis: Theory, Method and Research: Understanding Method and Application. London: Sage.
44. The EuroQol Group (1990). EuroQol - A new facility for the measurement of health-related quality of life. Health Policy 16: 199-208.
45. Thompson B (2011). Education and learning for people with ankylosing spondylitis. Available at http://hdl.handle.net/10443/1590 [Accessed March 2014].
46. Waldron N, Brown S, Hewlett S, Elliott B, McHugh N, McCabe C (2012). 'To suddenly have a name for this thing...was wonderful': The patient's experience of receiving a diagnosis of systemic lupus erythematosus. Musculoskeletal Care 10: 135-41.
47. Williams S (2000). Chronic illness as a biographical disruption or biographical disruption as chronic illness? Reflections on a core concept. Sociology of Health and Illness 22: 40-67.
48. Wolff-Michael R (2012). First person methods. Towards an empirical phenomenology of experience. Practice of Research Method 3. ISBN:978-94-6091-831-5 (online). Rotterdam, The Netherlands: Sense Publishers.
49. Zigmond AS, Snaith RP (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 67: 361-70.